EGFR-IN-44(Compound 6a)是一种有效的、具有口服活性的 EGFR tyrosine kinase 抑制剂,IC50 值为 4.11 nM,可诱导细胞凋亡 (apoptosis),口服生物利用度为 33.57%,可用于非小细胞肺癌的研究。
EGFR-IN-44
产品编号: MS-H40602 分子式: C27H29ClN6O2S 分子量: 537.08
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

EGFR-IN-44(Compound 6a)是一种有效的、具有口服活性的 EGFR tyrosine kinase 抑制剂,IC50 值为 4.11 nM,可诱导细胞凋亡 (apoptosis),口服生物利用度为 33.57%,可用于非小细胞肺癌的研究。

生物实验数据

生物活性 EGFR-IN-44 (Compound 6a) is a potent and orally active EGFR tyrosine kinase inhibitor with an IC50 value of 4.11 nM that induces apoptosis and has an oral bioavailability of 33.57%, and can be used for research on non-small cell lung cancer.
IC50 & Target

IC50: 0.26 nM (EGFR T790M/L858R), 1.33 nM (EGFR L858R), 4.11 nM (EGFR)

体外研究
(In Vitro)

EGFR-IN-44 (Compound 6a) (0-10 µM, 72 h) shows anti-proliferative activities against tumor cell lines.
EGFR-IN-44 binds to the ATP binding site of EGFR.
EGFR-IN-44 (0-10 nM, 48 h) induces H1975 cell apoptosis via the mitochondrial pathway, arrests cell cycle in G0/G1 phase, and suppresses cell migration.
EGFR-IN-44 (0-10 nM, 48 and 72h) shows hypotoxicity against normal cells.

Cell Proliferation Assay

Cell Line: H1975 (EGFRT790M/L858R), PC9 (EGFRdel19), and H292 (EGFRWT)
Concentration: 0-10 µM
Incubation Time: 72 h
Result: Showed anti-proliferative activities with IC50 values of 0.0022 ± 0.001, 0.0048 ± 0.001, and 4.499 ± 0.057 µM against H1975, PC9, and H292 cells, respectively.

Apoptosis Analysis

Cell Line: H1975
Concentration: 1, 5, and 10 nM
Incubation Time: 48 h
Result: Effectively induced cell apoptosis in a dose-dependent manner. Resulted in 33.7%, 52.4%, and 56.2% apoptosis at 1, 5, and 10 µM, respectively, compared to 5.81% apoptosis in the control group.

Western Blot Analysis

Cell Line: H1975
Concentration: 5, 10, and 25 nM
Incubation Time: 48 h and 72 h
Result: Dose-dependently upregulated the expression levels of the proapoptotic proteins Bad and Bax and downregulated the expression level of the antiapoptotic protein Bcl-2. Sufficiently reduced the phosphorylation of EGFR and AKT.

Cell Cycle Analysis

Cell Line: H1975
Concentration: 5 nM
Incubation Time: 0, 12, 24, or 48 h
Result: Exhibited a significant increase in the G0/G1 cell population and a dramatic decrease in G2/M phase.

Cell Cytotoxicity Assay

Cell Line: LO2, HK2, HLF, and 293A
Concentration: 0.1, 1, 5, and 10 µM
Incubation Time: 48 h and 72 h
Result: Showed hypotoxicity with IC50 values of 7.247, 4.586, 3.787, and 2.925 µM against LO2, HK2, HLF, and 293A cells, respectively. The cell morphology was changed compared to the control.
体内研究
(In Vivo)

EGFR-IN-44 (Compound 6a) (25 mg/kg; i.g.; daily, 7days) shows strong antitumor activity without obvious toxicity.

Animal Model: Male BALB/c nude mice (5 weeks old, 18 - 20 g), H1975 xenograft model
Dosage: 25 mg/kg
Administration: Intragastric administration, daily, 7 days
Result: Showed strong tumor inhibition (TGI = 90.24%) without obvious toxicity.
Animal Model: Male Sprague–Dawley (SD) rats
Dosage: 1 mg/kg and 5 mg/kg
Administration: Intravenous injection and oral administration (Pharmacokinetic Analysis)
Result: In Vivo PK parameters of EGFR-IN-44
Parameters
Dose(mg/kg)
EGFR-IN-44
5 (po)

1 (iv)
t1/2 (h) 8.60 ± 1.8 1.42 ± 0.1
Tmax (h) 4.00 ± 0.002 /
Cmax (ng/mL) 80.40 ± 2.7 /
Vz F_pred (L/kg) 220.80 ± 41.2 6.83 ± 08
AUC0-t (H.ng/mL) 490.41 ± 29.9 291.91 ± 38.2
AUC0-∞ (H.ng/mL) 491.02 ± 44.2 295.76 ± 38.8
MRT0-last (h) 7.93 ± 0.8 1.35 ± 01
CL (mL/h/kg) 17.79 ± 3.9 3.12 ± 0.4
F(%) 33.57 ± 5.9 /

F = (AUC0-inf-PO × DOSEIV)/(AUC0-inf-IV × DOSE PO)*100%.

化学信息

分子量 537.08
分子式 C27H29ClN6O2S

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础